The Anti-Diabetes Drugs market in New Zealand has been experiencing steady growth in recent years.
Customer preferences: New Zealand has a high prevalence of diabetes, with approximately 200,000 people diagnosed with the disease. As a result, there is a strong demand for anti-diabetes drugs in the country. Patients prefer drugs that are effective in controlling blood sugar levels, have minimal side effects, and are affordable.
Trends in the market: The market for anti-diabetes drugs in New Zealand is dominated by big pharmaceutical companies. However, there has been a recent trend towards the use of generic drugs. This is due to the fact that generic drugs are more affordable and have the same efficacy as their branded counterparts. In addition, the government has been encouraging the use of generic drugs to reduce healthcare costs.Another trend in the market is the increasing use of combination therapies. Combination therapies are drugs that combine two or more medications into one pill. This approach has been shown to be more effective in controlling blood sugar levels than using a single drug. Patients prefer combination therapies as they are more convenient and easier to manage.
Local special circumstances: New Zealand has a unique healthcare system, with a mix of public and private healthcare providers. The government provides subsidies for certain medications, including anti-diabetes drugs, which makes them more affordable for patients. However, there are still some patients who cannot afford these medications and rely on charitable organizations for assistance.
Underlying macroeconomic factors: The New Zealand economy has been growing steadily in recent years, which has led to an increase in healthcare spending. This has allowed the government to provide subsidies for medications, including anti-diabetes drugs. In addition, the aging population in New Zealand has led to an increase in the prevalence of chronic diseases such as diabetes, which has contributed to the growth of the anti-diabetes drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
